Log in with your email address username.


[Correspondence] Bioresorbable vascular scaffolds and late lumen loss

In the ABSORB II trial pubilished in The Lancet, Patrick Serruys and colleagues (Nov 19, p 2479)1 concluded that compared with everolimus-eluting metallic stents, everolimus-eluting bioresorbable vascular scaffolds (BVSs) were inferior because the late luminal loss at 3 years was greater with the BVSs. However, one of the major risk factors for late luminal loss is under expansion of the stent at implantation, which can be attenuated by using optimum implantation techniques such as the use of routine intravascular imaging modalities (ie, intravascular ultrasound or optical coherence tomography) and high-pressure postdilatation.